§329-18  Schedule III.  (a)  The
controlled substances listed in this section are included in schedule III.



(b)  Stimulants.  Unless listed in another
schedule, any material, compound, mixture, or preparation which contains any
quantity of the following substances having a stimulant effect on the central
nervous system, including their salts, isomers, and salts of isomers, whenever
the existence of these salts, isomers, and salts of isomers is possible within
the specific chemical designation:



(1)  Those compounds, mixtures, or preparations in
dosage unit form containing any stimulant substance listed in schedule II, and
any other drug of the quantitative composition or which is the same except that
it contains a lesser quantity of controlled substances;



(2)  Benzphetamine;



(3)  Chlorphentermine;



(4)  Clortermine;



(5)  Mazindol;



(6)  Phendimetrazine.



(c) 
Depressants.  Unless listed in another schedule, any material, compound,
mixture, or preparation containing any quantity of the following substances
having a depressant effect on the central nervous system:



(1)  Any compound, mixture, or preparation containing
amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more
other active medicinal ingredients which are not listed in any schedule;



(2)  Any suppository dosage form containing
amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and
approved by the Food and Drug Administration for marketing only as a
suppository;



(3)  Any substance that contains any quantity of a
derivative of barbituric acid or any salt thereof, including the substance
butalbital;



(4)  Chlorhexadol;



(5)  Embutramide (Tributame);



(6)  Ketamine, its salts, isomers, and salts of
isomers, also known as (+ or -)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;



(7)  Lysergic acid;



(8)  Lysergic acid amide;



(9)  Methyprylon;



(10)  Sulfondiethylmethane;



(11)  Sulfonethylmethane;



(12)  Sulfonmethane;



(13)  Tiletamine/Zolazepam (Telazol,
2-(ethylamino)-2-(-thienyl)-cyclohexanone, flupyrazapon) or any salts thereof;
and



(14)  Gamma
hydroxybutyric acid and its salts, isomers, and salts of isomers that are
contained in a drug product for which an application has been approved under
section 505 of the federal Food, Drug, and Cosmetic Act.



(d)  Nalorphine.



(e)  Narcotic drugs.  Unless specifically
excepted or unless listed in another schedule, any material, compound, mixture,
or preparation containing any of the following narcotic drugs, or their salts,
or alkaloid, in limited quantities as set forth below:



(1)  Not more than 1.8 grams of codeine, or any of its
salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with
an equal or greater quantity of an isoquinoline alkaloid of opium;



(2)  Not more than 1.8 grams of codeine, or any of its
salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with
one or more active, nonnarcotic ingredients in recognized therapeutic amounts;



(3)  Not more than 300 milligrams of dihydrocodeinone
(Hydrocodone), or any of its salts, per 100 milliliters or not more than 15
milligrams per dosage unit, with a fourfold or greater quantity of an
isoquinoline alkaloid of opium provided that these narcotic drugs shall be
monitored pursuant to section 329-101;



(4)  Not more than 300 milligrams of dihydrocodeinone
(Hydrocodone), or any of its salts per 100 milliliters or not more than 15
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts provided that these narcotic drugs shall be
monitored pursuant to section 329-101;



(5)  Not more than 1.8 grams of dihydrocodeine, or any
of its salts, per 100 milliliters or not more than 90 milligrams per dosage
unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;



(6)  Not more than 300 milligrams of ethylmorphine, or
any of its salts, per 100 milliliters or not more than 15 milligrams per dosage
unit, with one or more ingredients in recognized therapeutic amounts;



(7)  Not more than 500 milligrams of opium per 100
milliliters or per 100 grams, or not more than 25 milligrams per dosage unit,
with one or more active nonnarcotic ingredients in recognized therapeutic
amounts;



(8)  Not more than
50 milligrams of morphine or any of its salts, per 100 milliliters or per 100
grams with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts; and



(9)  Buprenorphine.



(f)  The department of public safety may except
by rule any compound, mixture, or preparation containing any stimulant or
depressant substance listed in subsections (b) and (c) from the application of
all or any part of this chapter if the compound, mixture, or preparation
contains one or more active medicinal ingredients not having a stimulant or
depressant effect on the central nervous system, and if the admixtures are
included therein in combinations, quantity, proportion, or concentration that
vitiate the potential for abuse of the substances which have a stimulant or
depressant effect on the central nervous system.



(g)  Any
anabolic steroid.  The term "anabolic steroid" means any drug or
hormonal substance chemically and pharmacologically related to testosterone
(other than estrogens, progestins, and corticosteroids) that promotes muscle
growth, and includes:



(1)  Boldenone;



(2)  Clostebol (4-Chlorotestosterone);



(3)  Dehydrochlormethyltestosterone;



(4)  Dihydrotestosterone (4-dihydrotestosterone);



(5)  Drostanolone;



(6)  Ethylestrenol;



(7)  Fluoxymesterone;



(8)  Formebolone (Formyldienolone);



(9)  Mesterolone;



(10)  Methandranone;



(11)  Methandriol;



(12)  Methandrostenolone (Methandienone);



(13)  Methenolone;



(14)  Methyltestosterone;



(15)  Mibolerone;



(16)  Nandrolone;



(17)  Norethandrolone;



(18)  Oxandrolone;



(19)  Oxymesterone;



(20)  Oxymetholone;



(21)  Stanolone (Dihydrotestosterone);



(22)  Stanozolol;



(23)  Testolactone;



(24)  Testosterone;



(25)  Trenbolone;



(26)  3[beta], 17-dihydroxy-5a-androstane;



(27)  3[alpha], 17[beta]-dihydroxy-5a-androstane;



(28)  5[alpha]-androstan-3, 17-dione;



(29)  1-androstenediol (3[beta], 17[beta]-dihydroxy-5[alpha]-androst-1-ene);



(30)  1-androstenediol (3[alpha],
17[beta]-dihydroxy-5[alpha]-androst-1-ene);



(31)  4-androstenediol (3[beta],
17[beta]-dihydroxy-androst-4-ene);



(32)  5-androstenediol (3[beta],
17[beta]-dihydroxy-androst-5-ene);



(33)  1-androstenedione ([5[alpha]]-androst-1-en-3,
17-dione);



(34)  4-androstenedione (androst-4-en-3, 17-dione);



(35)  5-androstenedione (androst-5-en-3, 17-dione);



(36)  Bolasterone (7[alpha],
17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);



(37)  Calusterone (7[beta],
17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);



(38)  [Delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);



(39)  Furazabol
(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan);



(40)  13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;



(41)  4-hydroxytestosterone
(4,17[beta]-dihydroxy-androst-4-en-3-one);



(42)  4-hydroxy-19-nortestosterone
(4,17[beta]-dihydroxy-estr-4-en-3-one);



(43)  Mesterolone
(1[alpha]methyl-17[beta]-hydroxy-[5[alpha]]-androstan-3-one);



(44)  Methandienone
(17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);



(45)  Methandriol (17[alpha]-methyl-3[beta],
17[beta]-dihydroxyandrost-5-ene);



(46)  Methenolone
(1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);



(47)  17[alpha]-methyl-3[beta],
17[beta]-dihydroxy-5a-androstane;



(48)  17[alpha]-methyl-3[alpha],
17[beta]-dihydroxy-5a-androstane;



(49)  17[alpha]-methyl-3[beta],
17[beta]-dihydroxyandrost-4-ene;



(50)  17[alpha]-methyl-4-hydroxynandrolone
(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);



(51)  Methyldienolone
(17[alpha]-methyl-17[beta]-hydroxyestra-4, 9(10)-dien-3-one);



(52)  Methyltrienolone
(17[alpha]-methyl-17[beta]-hydroxyestra-4, 9-11-trien-3-one);



(53)  17[alpha]-methyl-[Delta] 1-dihydrotestosterone
(17b [beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a.
'17-[alpha]-methyl-1-testosterone');



(54)  19-nor-4-androstenediol (3[beta],
17[beta]-dihydroxyestr-4-ene);



(55)  19-nor-4-androstenediol (3[alpha],
17[beta]-dihydroxyestr-4-ene);



(56)  19-nor-5-androstenediol (3[beta],
17[beta]-dihydroxyestr-5-ene);



(57)  19-nor-5-androstenediol (3[alpha],
17[beta]-dihydroxyestr-5-ene);



(58)  19-nor-4-androstenedione (estr-4-en-3, 17-dione);



(59)  19-nor-5-androstenedione (estr-5-en-3, 17-dione);



(60)  Norbolethone (13[beta],
17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);



(61)  Norclostebol
(4-chloro-17[beta]-hydroxyestr-4-en-3-one);



(62)  Normethandrolone
(17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);



(63)  Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one);



(64)  Tetrahydrogestrinone (13[beta],
17[alpha]-diethyl-17[beta]-hydroxygon-4, 9, 11-trien-3-one); and



(65)  Any salt,
ester, or isomer of a drug or substance described or listed in this subsection,
if that salt, ester, or isomer promotes muscle growth, except the term "anabolic steroid" does not include an anabolic steroid which is
expressly intended for administration through implants to cattle or other
nonhuman species and which has been approved by the Secretary of Health and
Human Services for nonhuman administration.  If any person prescribes,
dispenses, or distributes an anabolic steroid intended for administration to
nonhuman species for human use, the person shall be considered to have
prescribed, dispensed, or distributed an anabolic steroid within the meaning of
this paragraph.



(h)  Hallucinogenic substances, unless listed
in another schedule, shall include Dronabinol (synthetic), in sesame oil and
encapsulated in a soft gelatin capsule in a United States Food and Drug
Administration approved drug product. [L 1972, c 10, pt of §1 and am c 114,
§2(1); am L 1974, c 217, §3; am L 1975, c 26, §2; am L 1977, c 116, §2; am L
1978, c 68, §4; am L 1988, c 59, §3; am L 1990, c 281, §10; am L 1991, c 159,
§8; am L 1992, c 151, §1; am L 1995, c 122, §3; am L 1997, c 356, §§3, 4; am L
2000, c 98, §4; am L 2001, c 203, §4; am L 2003, c 151, §4; am L 2004, c 193,
§2; am L 2008, c 186, §3; am L 2009, c 117, §3]



 



Revision Note



 



  In subsection (g)(59), a closing parenthesis was added after
the word "dione".